---
theme: academic
layout: cover
class: text-white
coverAuthor: beau hilton
coverAuthorUrl: https://www.beauhilton.com
coverDate: "2024-02-02"
themeConfig:
  paginationX: r
  paginationY: t
  paginationPagesDisabled: [1]
title: RM-HNSCC
info: |
  # RM-HNSCC
  Case Conference 2024-02-02, [Beau Hilton](https://www.beauhilton.com)

---

# Recurrent/Metastatic HNSCC

---

# Case presentation

60M,
prev heavy tob use (dip x40y, quit 1y prior to dx),
prev heavy EtOH use (6x/d, quit at time of dx),
presented for routine dental care.

Dentist noted gingival lesion,
iso 1-2y of gum recession, bleeding, loose teeth.

<v-clicks>

- Bx: mod diff SCC
- Staging -ve for distant disease.
- Resected a couple of months later
    - L floor of mouth, buccal mucosa, mandible w glossectomy, L neck dissection
    - R0

</v-clicks>


---
layout: figure-side
figureFootnoteNumber: 1
figureUrl: ./images/king-crimson.png
---

# The Oral Cavity?


---
layout: figure-side
figureFootnoteNumber: 1
figureUrl: ./images/mda-oral-cavity.jpg
---

# The Oral Cavity?

<v-clicks>

- localization can be tough
- thank goodness for surgeons and pathologists
- imaging alone may underdiagnose/be misleading
- direct exam
- resection
- path matters (e.g. vermilion border SCC may be cSCC, not tx like OCC)

</v-clicks>

---

# Oral Cavity - TN(M) Staging

| T                                                                                      | N
|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------
| T1 - <=2cm, DOI <=5mm                                                                  | N1 - single ipsilateral, <=3cm, ENE- | T1 - <=2cm, DOI <=5mm
| T2 - <=2cm, DOI >5mm; >2cm <=4cm, DOI <=10mm                                           | N2a - single ipsilateral and [<=3cm, ENE+] or [>3cm <6cm, ENE-]
| T3 - >2cm <=4cm, DOI >10mm; >4cm, DOI <=10mm                                           | N2b - multiple ipsilateral, <=6cm, ENE-
| T4a - >4cm, DOI >10mm; invades adjacent structures only                                | N2c - bilateral/contralateral, <=6cm, ENE-
| T4b - invades masticator space, pterygoid plates, skull base, encases internal carotid | N3a - >6cm, ENE-
|                                                                                        | N3b - single ipsilateral >3cm, ENE+; multiple ipsi/contra/bilateral any ENE+; or single contralateral ENE+

---

# First resection results

- pT4a pN1 (stage IVA)
- offered but declined adjuvant CRT

---

# First recurrence

About 6mo later, local recurrence.

Re-resected, R0, rpT3 -> CRT (carbo -> cisplatin q7d)


---

# Second recurrence

Just <6mo later, another local recurrence.

<v-clicks>

- Re-resected, R0, 2/5LN+ (1.7cm), +PNI
- Pembro monotherapy recommended
- Insurance said no
- (TMB 9.5, MSS, CPS 5)

</v-clicks>

---

# Pembrolizumab approvals

- 2014-09-04: initial approval (for melanoma progressed on ipi or BRAF TKI - KEYNOTE-002)
- <p style="color:red;"> 2016-08-05: HNSCC: monotherapy for platinum-refractory RM-HNSCC (KEYNOTE-012)</p>
- 2017-05-23: all MSI-H/dMMR with POD and no other great tx
- <p style="color:red;"> 2019-06-10: HNSCC: +platinum + FU for all; monotherapy for CPS >=1 (KEYNOTE-048)</p>
- 2020-06-16: all TMB >=10 with POD and no other great tx
- 2024-01-12: newest indication (pembro + CRT for stage III-IVA cervical cancer)


<div class="text-xs" style="line-height: 1.35; margin-top: 2em;">

- [Current FDA label pdf link (Drugs@FDA)](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514)
- [Current FDA label web link (DailyMed)](https://dailymed.nlm.nih.gov/dailymed/)
- FDA approval announcement links:
    - [2013 - 2016](https://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm)
    - [2017 - 2020](https://wayback.archive-it.org/7993/20201219232235/https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications)
    - [2020 - present](https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications)
</div>


---

# KEYNOTE-012

<div class="container mx-auto grid gap-4 grid-cols-2">
<div>
<img class="flex items-center w-100 h-75 hover:scale-130 hover:opacity-100" src="/images/keynote-012-01.png" />
<div class="text-xs text-center">Lancet Oncology 2016</div>
</div>
<div>
<img class="flex items-center w-100 h-75 hover:scale-130 hover:opacity-100" src="/images/keynote-012-02.png" />
<div class="text-xs text-center">British Journal of Cancer 2018</div>
</div>
</div>



---

# Progression

<v-clicks>

- Seeking insurance approval delayed start of therapy x1mo.
- Developed dermal mets, overall rapidly progressive disease.
- --> KEYNOTE-B10 + Quad-Shot RT

</v-clicks>


---

# KEYNOTE-B10 (1L R/M, carbo+taxol+pembro)

<div class="container mx-auto grid gap-4 grid-cols-2">
<div>
<img class="flex items-center w-100 h-75 hover:scale-130 hover:opacity-100" src="/images/keynote-b10-02.png" />
<div class="text-xs text-center">Annals of Oncology 2022</div>
</div>
<div>
<img class="flex items-center w-170 h-75 hover:scale-130 hover:opacity-100" src="/images/keynote-b10-01.png" />
<div class="text-xs text-center">ESMO 2022</div>
</div>
</div>

---

# Current

- dermal mets no longer apparent
- primary appears to be shrinking (clinically and by PET)
- delayed C6 d/t mucositis -> AKI ~10d after quad-shot
- planning pembro maintenance and close observation

---

# Bibliography

<div class="csl-bib-body text-sm" style="line-height: 1.35; margin-left: 2em; text-indent:-2em;">

  <div class="csl-entry">Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., Castro, G. de, Psyrri, A., Basté, N., Neupane, P., Bratland, Å., Fuereder, T., Hughes, B. G. M., Mesía, R., Ngamphaiboon, N., Rordorf, T., Ishak, W. Z. W., Hong, R.-L., Mendoza, R. G., Roy, A., … Yorio, J. (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. <i>The Lancet</i>, <i>394</i>(10212), 1915–1928. <a href="https://doi.org/10.1016/S0140-6736(19)32591-7">https://doi.org/10.1016/S0140-6736(19)32591-7</a></div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736(19)32591-7&amp;rft_id=info%3Apmid%2F31679945&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Pembrolizumab%20alone%20or%20with%20chemotherapy%20versus%20cetuximab%20with%20chemotherapy%20for%20recurrent%20or%20metastatic%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20(KEYNOTE-048)%3A%20a%20randomised%2C%20open-label%2C%20phase%203%20study&amp;rft.jtitle=The%20Lancet&amp;rft.stitle=The%20Lancet&amp;rft.volume=394&amp;rft.issue=10212&amp;rft.aufirst=Barbara&amp;rft.aulast=Burtness&amp;rft.au=Barbara%20Burtness&amp;rft.au=Kevin%20J.%20Harrington&amp;rft.au=Richard%20Greil&amp;rft.au=Denis%20Souli%C3%A8res&amp;rft.au=Makoto%20Tahara&amp;rft.au=Gilberto%20de%20Castro&amp;rft.au=Amanda%20Psyrri&amp;rft.au=Neus%20Bast%C3%A9&amp;rft.au=Prakash%20Neupane&amp;rft.au=%C3%85se%20Bratland&amp;rft.au=Thorsten%20Fuereder&amp;rft.au=Brett%20G.%20M.%20Hughes&amp;rft.au=Ricard%20Mes%C3%ADa&amp;rft.au=Nuttapong%20Ngamphaiboon&amp;rft.au=Tamara%20Rordorf&amp;rft.au=Wan%20Zamaniah%20Wan%20Ishak&amp;rft.au=Ruey-Long%20Hong&amp;rft.au=Ren%C3%A9%20Gonz%C3%A1lez%20Mendoza&amp;rft.au=Ananya%20Roy&amp;rft.au=Yayan%20Zhang&amp;rft.au=Burak%20Gumuscu&amp;rft.au=Jonathan%20D.%20Cheng&amp;rft.au=Fan%20Jin&amp;rft.au=Danny%20Rischin&amp;rft.au=Guillermo%20Lerzo&amp;rft.au=Marcelo%20Tatangelo&amp;rft.au=Mirta%20Varela&amp;rft.au=Juan%20Jose%20Zarba&amp;rft.au=Michael%20Boyer&amp;rft.au=Hui%20Gan&amp;rft.au=Bo%20Gao&amp;rft.au=Brett%20Hughes&amp;rft.au=Girish%20Mallesara&amp;rft.au=Danny%20Rischin&amp;rft.au=Anne%20Taylor&amp;rft.au=Martin%20Burian&amp;rft.au=Thorsten%20Fuereder&amp;rft.au=Richard%20Greil&amp;rft.au=Carlos%20Henrique%20Barrios&amp;rft.au=Dalvaro%20Oliveira%20de%20Castro%20Junior&amp;rft.au=Gilberto%20Castro&amp;rft.au=Fabio%20Andre%20Franke&amp;rft.au=Gustavo%20Girotto&amp;rft.au=Iane%20Pinto%20Figueiredo%20Lima&amp;rft.au=Ulisses%20Ribaldo%20Nicolau&amp;rft.au=Gustavo%20Dix%20Junqueira%20Pinto&amp;rft.au=Lucas%20Santos&amp;rft.au=Ana-Paula%20Victorino&amp;rft.au=Neil%20Chua&amp;rft.au=Felix%20Couture&amp;rft.au=Richard%20Gregg&amp;rft.au=Aaron%20Hansen&amp;rft.au=John%20Hilton&amp;rft.au=Joy%20McCarthy&amp;rft.au=Denis%20Soulieres&amp;rft.au=Rodrigo%20Ascui&amp;rft.au=Pablo%20Gonzalez&amp;rft.au=Luis%20Villanueva&amp;rft.au=Marco%20Torregroza&amp;rft.au=Angela%20Zambrano&amp;rft.au=Petra%20Holeckova&amp;rft.au=Zdenek%20Kral&amp;rft.au=Bohuslav%20Melichar&amp;rft.au=Jana%20Prausova&amp;rft.au=Milan%20Vosmik&amp;rft.au=Maria%20Andersen&amp;rft.au=Niels%20Gyldenkerne&amp;rft.au=Hannes%20Jurgens&amp;rft.au=Kadri%20Putnik&amp;rft.au=Petri%20Reinikainen&amp;rft.au=Viktor%20Gruenwald&amp;rft.au=Simon%20Laban&amp;rft.au=Gerasimos%20Aravantinos&amp;rft.au=Ioannis%20Boukovinas&amp;rft.au=Vassilis%20Georgoulias&amp;rft.au=Amanda%20Psyrri&amp;rft.au=Dora%20Kwong&amp;rft.au=Yousuf%20Al-Farhat&amp;rft.au=Tibor%20Csoszi&amp;rft.au=Jozsef%20Erfan&amp;rft.au=Geza%20Horvai&amp;rft.au=Laszlo%20Landherr&amp;rft.au=Eva%20Remenar&amp;rft.au=Agnes%20Ruzsa&amp;rft.au=Judit%20Szota&amp;rft.au=Salem%20Billan&amp;rft.au=Iris%20Gluck&amp;rft.au=Orit%20Gutfeld&amp;rft.au=Aron%20Popovtzer&amp;rft.au=Marco%20Benasso&amp;rft.au=Simona%20Bui&amp;rft.au=Vittorio%20Ferrari&amp;rft.au=Lisa%20Licitra&amp;rft.au=Franco%20Nole&amp;rft.au=Takashi%20Fujii&amp;rft.au=Yasushi%20Fujimoto&amp;rft.au=Nobuhiro%20Hanai&amp;rft.au=Hiroki%20Hara&amp;rft.au=Koji%20Matsumoto&amp;rft.au=Kenji%20Mitsugi&amp;rft.au=Nobuya%20Monden&amp;rft.au=Masahiro%20Nakayama&amp;rft.au=Kenji%20Okami&amp;rft.au=Nobuhiko%20Oridate&amp;rft.au=Kiyoto%20Shiga&amp;rft.au=Yasushi%20Shimizu&amp;rft.au=Masashi%20Sugasawa&amp;rft.au=Makoto%20Tahara&amp;rft.au=Masanobu%20Takahashi&amp;rft.au=Shunji%20Takahashi&amp;rft.au=Kaoru%20Tanaka&amp;rft.au=Tsutomu%20Ueda&amp;rft.au=Hironori%20Yamaguchi&amp;rft.au=Tomoko%20Yamazaki&amp;rft.au=Ryuji%20Yasumatsu&amp;rft.au=Tomoya%20Yokota&amp;rft.au=Tomokazu%20Yoshizaki&amp;rft.au=Iveta%20Kudaba&amp;rft.au=Zinaida%20Stara&amp;rft.au=Wan%20Zamaniah%20Wan%20Ishak&amp;rft.au=Soon%20Keat%20Cheah&amp;rft.au=Jose%20Aguilar%20Ponce&amp;rft.au=Rene%20Gonzalez%20Mendoza&amp;rft.au=Carlos%20Hernandez%20Hernandez&amp;rft.au=Francisco%20Medina%20Soto&amp;rft.au=Jan%20Buter&amp;rft.au=Ann%20Hoeben&amp;rft.au=S.%20Oosting&amp;rft.au=Karijn%20Suijkerbuijk&amp;rft.au=Aase%20Bratland&amp;rft.au=Marianne%20Brydoey&amp;rft.au=Renzo%20Alvarez&amp;rft.au=Luis%20Mas&amp;rft.au=Priscilla%20Caguioa&amp;rft.au=John%20Querol&amp;rft.au=Eugenio%20Emmanuel%20Regala&amp;rft.au=Maria%20Belen%20Tamayo&amp;rft.au=Ellie%20May%20Villegas&amp;rft.au=Andrzej%20Kawecki&amp;rft.au=Andrey%20Karpenko&amp;rft.au=Arkadiy%20Klochikhin&amp;rft.au=Alexey%20Smolin&amp;rft.au=Oleg%20Zarubenkov&amp;rft.au=Boon%20Cher%20Goh&amp;rft.au=Graham%20Cohen&amp;rft.au=Johanna%20du%20Toit&amp;rft.au=Christa%20Jordaan&amp;rft.au=Gregory%20Landers&amp;rft.au=Paul%20Ruff&amp;rft.au=Waldemar%20Szpak&amp;rft.au=Neonyana%20Tabane&amp;rft.au=Irene%20Brana&amp;rft.au=Lara%20Iglesias%20Docampo&amp;rft.au=Javier%20Lavernia&amp;rft.au=Ricard%20Mesia&amp;rft.au=Edvard%20Abel&amp;rft.au=Valentina%20Muratidu&amp;rft.au=Niels%20Nielsen&amp;rft.au=Valerie%20Cristina&amp;rft.au=Tamara%20Rordorf&amp;rft.au=Sacha%20Rothschild&amp;rft.au=Ruey-Long%20Hong&amp;rft.au=Hung-Ming%20Wang&amp;rft.au=Muh-Hwa%20Yang&amp;rft.au=Su-Peng%20Yeh&amp;rft.au=Chia-Jui%20Yen&amp;rft.au=Nuttapong%20Ngamphaiboon&amp;rft.au=Nopadol%20Soparattanapaisarn&amp;rft.au=Virote%20Sriuranpong&amp;rft.au=Sercan%20Aksoy&amp;rft.au=Irfan%20Cicin&amp;rft.au=Meltem%20Ekenel&amp;rft.au=Hakan%20Harputluoglu&amp;rft.au=Ozgur%20Ozyilkan&amp;rft.au=Kevin%20Harrington&amp;rft.au=Sanjiv%20Agarwala&amp;rft.au=Haythem%20Ali&amp;rft.au=Robert%20Alter&amp;rft.au=Daniel%20Anderson&amp;rft.au=Justine%20Bruce&amp;rft.au=Barbara%20Burtness&amp;rft.au=Nicholas%20Campbell&amp;rft.au=Miguel%20Conde&amp;rft.au=John%20Deeken&amp;rft.au=William%20Edenfield&amp;rft.au=Lawrence%20Feldman&amp;rft.au=Elizabeth%20Gaughan&amp;rft.au=Basem%20Goueli&amp;rft.au=Balazs%20Halmos&amp;rft.au=Upendra%20Hegde&amp;rft.au=Brian%20Hunis&amp;rft.au=Robert%20Jotte&amp;rft.au=Anand%20Karnad&amp;rft.au=Saad%20Khan&amp;rft.au=Noel%20Laudi&amp;rft.au=Douglas%20Laux&amp;rft.au=Danko%20Martincic&amp;rft.au=Steven%20McCune&amp;rft.au=Dean%20McGaughey&amp;rft.au=Krzysztof%20Misiukiewicz&amp;rft.au=Deborah%20Mulford&amp;rft.au=Eric%20Nadler&amp;rft.au=Prakash%20Neupane&amp;rft.au=Johannes%20Nunnink&amp;rft.au=James%20Ohr&amp;rft.au=Meaghan%20O'Malley&amp;rft.au=Brian%20Patson&amp;rft.au=Doru%20Paul&amp;rft.au=Elizabeta%20Popa&amp;rft.au=Steven%20Powell&amp;rft.au=Rebecca%20Redman&amp;rft.au=Vincent%20Rella&amp;rft.au=Chaio%20Rocha%20Lima&amp;rft.au=Abirami%20Sivapiragasam&amp;rft.au=Yungpo%20Su&amp;rft.au=Ammar%20Sukari&amp;rft.au=Stuart%20Wong&amp;rft.au=Emrullah%20Yilmaz&amp;rft.au=Jeffrey%20Yorio&amp;rft.date=2019-11-23&amp;rft.pages=1915-1928&amp;rft.spage=1915&amp;rft.epage=1928&amp;rft.issn=0140-6736%2C%201474-547X&amp;rft.language=English"></span>
  <div class="csl-entry">Cabezas-Camarero, S., Merino-Menéndez, S., Cabrera-Martín, M. N., Sotelo, M. J., Plaza-Hernández, J. C., Falahat, F., Iglesias-Moreno, M. C., &amp; Pérez-Segura, P. (2022). Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer. <i>Oncology Letters</i>, <i>25</i>(1), 37. <a href="https://doi.org/10.3892/ol.2022.13623">https://doi.org/10.3892/ol.2022.13623</a></div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.3892%2Fol.2022.13623&amp;rft_id=info%3Apmid%2F36589672&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Safety%20and%20preliminary%20activity%20of%20pembrolizumab-carboplatin-paclitaxel%20in%20heavily%20pretreated%20and%2For%20fragile%20patients%20with%20PDL1-positive%20recurrent%2Fmetastatic%20head%20and%20neck%20cancer&amp;rft.jtitle=Oncology%20Letters&amp;rft.stitle=Oncol%20Lett&amp;rft.volume=25&amp;rft.issue=1&amp;rft.aufirst=Santiago&amp;rft.aulast=Cabezas-Camarero&amp;rft.au=Santiago%20Cabezas-Camarero&amp;rft.au=Salom%C3%A9%20Merino-Men%C3%A9ndez&amp;rft.au=Mar%C3%ADa%20Nieves%20Cabrera-Mart%C3%ADn&amp;rft.au=Miguel%20J.%20Sotelo&amp;rft.au=Jos%C3%A9%20Carlos%20Plaza-Hern%C3%A1ndez&amp;rft.au=Farzin%20Falahat&amp;rft.au=Mar%C3%ADa%20Cruz%20Iglesias-Moreno&amp;rft.au=Pedro%20P%C3%A9rez-Segura&amp;rft.date=2022-12-07&amp;rft.pages=37&amp;rft.issn=1792-1074"></span>
  <div class="csl-entry">Dzienis, M. R., Cundom, J. E., Fuentes, C. S., Hansen, A. R., Nordlinger, M. J., Pastor, A. V., Oppelt, P., Neki, A., Gregg, R. W., Lima, I. P. F., Franke, F. A., Junior, G. F. da C., Tseng, J. E., Loree, T., Joshi, A. J., Mccarthy, J. S., Naicker, N., Sidi, Y., Gumuscu, B., &amp; Castro, G. D. (2022). 651O Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study. <i>Annals of Oncology</i>, <i>33</i>, S839–S840. <a href="https://doi.org/10.1016/j.annonc.2022.07.775">https://doi.org/10.1016/j.annonc.2022.07.775</a></div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1016%2Fj.annonc.2022.07.775&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=651O%20Pembrolizumab%20(pembro)%20%2B%20carboplatin%20(carbo)%20%2B%20paclitaxel%20(pacli)%20as%20first-line%20(1L)%20therapy%20in%20recurrent%2Fmetastatic%20(R%2FM)%20head%20and%20neck%20squamous%20cell%20carcinoma%20(HNSCC)%3A%20Phase%20VI%20KEYNOTE-B10%20study&amp;rft.jtitle=Annals%20of%20Oncology&amp;rft.stitle=Annals%20of%20Oncology&amp;rft.volume=33&amp;rft.aufirst=M.%20R.&amp;rft.aulast=Dzienis&amp;rft.au=M.%20R.%20Dzienis&amp;rft.au=J.%20E.%20Cundom&amp;rft.au=C.%20S.%20Fuentes&amp;rft.au=A.%20R.%20Hansen&amp;rft.au=M.%20J.%20Nordlinger&amp;rft.au=A.%20V.%20Pastor&amp;rft.au=P.%20Oppelt&amp;rft.au=A.%20Neki&amp;rft.au=R.%20W.%20Gregg&amp;rft.au=I.%20P.%20F.%20Lima&amp;rft.au=F.%20A.%20Franke&amp;rft.au=G.%20F.%20da%20Cunha%20Junior&amp;rft.au=J.%20E.%20Tseng&amp;rft.au=T.%20Loree&amp;rft.au=A.%20J.%20Joshi&amp;rft.au=J.%20S.%20Mccarthy&amp;rft.au=N.%20Naicker&amp;rft.au=Y.%20Sidi&amp;rft.au=B.%20Gumuscu&amp;rft.au=G.%20De%20Castro&amp;rft.date=2022-09-01&amp;rft.pages=S839-S840&amp;rft.spage=S839&amp;rft.epage=S840&amp;rft.issn=0923-7534%2C%201569-8041&amp;rft.language=English"></span>
  <div class="csl-entry">Harrington, K. J., Burtness, B., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Brana, I., Basté, N., Neupane, P., Bratland, Å., Fuereder, T., Hughes, B. G. M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Lin, J., Gumuscu, B., … Rischin, D. (2023). Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. <i>Journal of Clinical Oncology</i>, <i>41</i>(4), 790–802. <a href="https://doi.org/10.1200/JCO.21.02508">https://doi.org/10.1200/JCO.21.02508</a></div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.21.02508&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Pembrolizumab%20With%20or%20Without%20Chemotherapy%20in%20Recurrent%20or%20Metastatic%20Head%20and%20Neck%20Squamous%20Cell%20Carcinoma%3A%20Updated%20Results%20of%20the%20Phase%20III%20KEYNOTE-048%20Study&amp;rft.jtitle=Journal%20of%20Clinical%20Oncology&amp;rft.stitle=JCO&amp;rft.volume=41&amp;rft.issue=4&amp;rft.aufirst=Kevin%20J.&amp;rft.aulast=Harrington&amp;rft.au=Kevin%20J.%20Harrington&amp;rft.au=Barbara%20Burtness&amp;rft.au=Richard%20Greil&amp;rft.au=Denis%20Souli%C3%A8res&amp;rft.au=Makoto%20Tahara&amp;rft.au=Gilberto%20de%20Castro&amp;rft.au=Amanda%20Psyrri&amp;rft.au=Irene%20Brana&amp;rft.au=Neus%20Bast%C3%A9&amp;rft.au=Prakash%20Neupane&amp;rft.au=%C3%85se%20Bratland&amp;rft.au=Thorsten%20Fuereder&amp;rft.au=Brett%20G.M.%20Hughes&amp;rft.au=Ricard%20Mesia&amp;rft.au=Nuttapong%20Ngamphaiboon&amp;rft.au=Tamara%20Rordorf&amp;rft.au=Wan%20Zamaniah%20Wan%20Ishak&amp;rft.au=Jianxin%20Lin&amp;rft.au=Burak%20Gumuscu&amp;rft.au=Ramona%20F.%20Swaby&amp;rft.au=Danny%20Rischin&amp;rft.date=2023-02&amp;rft.pages=790-802&amp;rft.spage=790&amp;rft.epage=802&amp;rft.issn=0732-183X"></span>
  <div class="csl-entry">Mehra, R., Seiwert, T. Y., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., Burtness, B., Tahara, M., Keam, B., Kang, H., Muro, K., Geva, R., Chung, H. C., Lin, C.-C., Aurora-Garg, D., Ray, A., Pathiraja, K., Cheng, J., Chow, L. Q. M., &amp; Haddad, R. (2018). Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i>, <i>119</i>(2), 153–159. <a href="https://doi.org/10.1038/s41416-018-0131-9">https://doi.org/10.1038/s41416-018-0131-9</a></div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1038%2Fs41416-018-0131-9&amp;rft_id=info%3Apmid%2F29955135&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Efficacy%20and%20safety%20of%20pembrolizumab%20in%20recurrent%2Fmetastatic%20head%20and%20neck%20squamous%20cell%20carcinoma%3A%20pooled%20analyses%20after%20long-term%20follow-up%20in%20KEYNOTE-012&amp;rft.jtitle=British%20Journal%20of%20Cancer&amp;rft.stitle=Br%20J%20Cancer&amp;rft.volume=119&amp;rft.issue=2&amp;rft.aufirst=Ranee&amp;rft.aulast=Mehra&amp;rft.au=Ranee%20Mehra&amp;rft.au=Tanguy%20Y.%20Seiwert&amp;rft.au=Shilpa%20Gupta&amp;rft.au=Jared%20Weiss&amp;rft.au=Iris%20Gluck&amp;rft.au=Joseph%20P.%20Eder&amp;rft.au=Barbara%20Burtness&amp;rft.au=Makoto%20Tahara&amp;rft.au=Bhumsuk%20Keam&amp;rft.au=Hyunseok%20Kang&amp;rft.au=Kei%20Muro&amp;rft.au=Ravit%20Geva&amp;rft.au=Hyun%20Cheol%20Chung&amp;rft.au=Chia-Chi%20Lin&amp;rft.au=Deepti%20Aurora-Garg&amp;rft.au=Archana%20Ray&amp;rft.au=Kumudu%20Pathiraja&amp;rft.au=Jonathan%20Cheng&amp;rft.au=Laura%20Q.%20M.%20Chow&amp;rft.au=Robert%20Haddad&amp;rft.date=2018-07&amp;rft.pages=153-159&amp;rft.spage=153&amp;rft.epage=159&amp;rft.issn=1532-1827&amp;rft.language=eng"></span>
  <div class="csl-entry">Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., Cheng, J. D., &amp; Chow, L. Q. (2016). Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. <i>The Lancet Oncology</i>, <i>17</i>(7), 956–965. <a href="https://doi.org/10.1016/S1470-2045(16)30066-3">https://doi.org/10.1016/S1470-2045(16)30066-3</a></div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1016%2FS1470-2045(16)30066-3&amp;rft_id=info%3Apmid%2F27247226&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Safety%20and%20clinical%20activity%20of%20pembrolizumab%20for%20treatment%20of%20recurrent%20or%20metastatic%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20(KEYNOTE-012)%3A%20an%20open-label%2C%20multicentre%2C%20phase%201b%20trial&amp;rft.jtitle=The%20Lancet%20Oncology&amp;rft.stitle=The%20Lancet%20Oncology&amp;rft.volume=17&amp;rft.issue=7&amp;rft.aufirst=Tanguy%20Y.&amp;rft.aulast=Seiwert&amp;rft.au=Tanguy%20Y.%20Seiwert&amp;rft.au=Barbara%20Burtness&amp;rft.au=Ranee%20Mehra&amp;rft.au=Jared%20Weiss&amp;rft.au=Raanan%20Berger&amp;rft.au=Joseph%20Paul%20Eder&amp;rft.au=Karl%20Heath&amp;rft.au=Terrill%20McClanahan&amp;rft.au=Jared%20Lunceford&amp;rft.au=Christine%20Gause&amp;rft.au=Jonathan%20D.%20Cheng&amp;rft.au=Laura%20Q.%20Chow&amp;rft.date=2016-07-01&amp;rft.pages=956-965&amp;rft.spage=956&amp;rft.epage=965&amp;rft.issn=1470-2045%2C%201474-5488&amp;rft.language=English"></span>

</div>
